Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab”

119 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 119 results

Testing effectiveness (Phase 2)Looking for participantsNCT07110064
What this trial is testing

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Who this might be right for
Advance Pancreatic Cancer
Du Juan 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07117877
What this trial is testing

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Who this might be right for
Platinum Resistant Ovarian CancerPlatinum Refractory Epithelial Ovarian CancerOvarian Cancer (OvCa)
Fudan University 33
Testing effectiveness (Phase 2)Looking for participantsNCT07014150
What this trial is testing

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Resectable
Peking Union Medical College Hospital 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416058
What this trial is testing

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Who this might be right for
Lung Adenocarcinoma
Guangdong Association of Clinical Trials 61
Testing effectiveness (Phase 2)Looking for participantsNCT06936748
What this trial is testing

SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors

Who this might be right for
Cancer
Second Affiliated Hospital of Nanchang University 30
Not applicableNot Yet RecruitingNCT07139587
What this trial is testing

The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Qingxia Li 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07131345
What this trial is testing

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Who this might be right for
Malignant MesotheliomaMesothelioma
National Cancer Center, China 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07135804
What this trial is testing

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

Who this might be right for
Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
Second Affiliated Hospital of Nanchang University 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07119931
What this trial is testing

A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07738159
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma

Who this might be right for
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)QL1706Lenvatinib+1 more
West China Hospital 92
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07271602
What this trial is testing

Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

Who this might be right for
Non Small Cell Lung CancerImmunotherapyRadiotherapy+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 104
Not applicableLooking for participantsNCT07546383
What this trial is testing

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
The Second Affiliated Hospital of Hainan Medical University 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07372079
What this trial is testing

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Who this might be right for
Breast CancerNeoadjuvant TherapyImmune Checkpoint Inhibitors+1 more
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07131501
What this trial is testing

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular CarcinomaImmunotherapyPreoperative+2 more
The First Affiliated Hospital with Nanjing Medical University 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07549906
What this trial is testing

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

Who this might be right for
Colon Cancer (Stage II &Amp; III)ImmunotherapyBeta Blocker+1 more
Sun Yat-sen University 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07493993
What this trial is testing

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Who this might be right for
ESCC
Tianjin Medical University Cancer Institute and Hospital 26
Not applicableNot Yet RecruitingNCT07046780
What this trial is testing

A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor CancerMetastatic Solid TumorsLocally Advanced
PENG YUAN 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07454018
What this trial is testing

Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian CancerPlatinum-sensitive Ovarian Cancer
The First Affiliated Hospital of Soochow University 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07530549
What this trial is testing

A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy

Who this might be right for
Local Advanced Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40
Testing effectiveness (Phase 2)Looking for participantsNCT06930118
What this trial is testing

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

Who this might be right for
Advanced Colorectal Cancer in the Third-line Treatment and BeyondpMMR/MSS Advanced Colorectal Cancer
Shanghai Changzheng Hospital 60
Next Page